Subjects with moderate hepatic impairment exhibit changes in roxadustat pharmacokinetics and pharmacodynamics relative to subjects with normal hepatic function.

These differences are not expected to be clinically significant or to warrant a different dosing strategy for subjects with moderate hepatic impairment.

The single 100 mg oral dose of roxadustat was generally well tolerated in subjects with moderate hepatic impairment and subjects with normal hepatic function.